Telesky-MCT 25/12.5 Tablets provide an established, clinically unified triple-combination therapy carefully developed for the continuous management and physiological stabilization of severe, chronic, or stubborn essential Hypertension. When dual regimens or single-agent therapies fail to maintain blood pressure within optimal targets, attacking cardiovascular dysfunction across multiple independent physiological loops is vital. This advanced oral formulation integrates three distinct, highly complementary anti-hypertensive agents to target arterial vascular resistance, fluid-volume excess, and sympathetic overactivity simultaneously, preventing sudden blood pressure fluctuations.
The synchronized formulation operates dynamically across three distinct physiological fronts:
-
Telmisartan: A selective angiotensin II type 1 ($AT_1$) receptor antagonist. It blocks the powerful vasoconstricting actions of angiotensin II, systematically relaxing arterial smooth muscle walls to drop peripheral vascular resistance without causing a reflex increase in heart rate.
-
Chlorthalidone (12.5 mg): A potent, long-acting thiazide-like diuretic. It works inside the kidneys at the cortical diluting segment of the distal convoluted tubule, blocking the active reabsorption of sodium and chloride ($Na^+/Cl^-$ cotransporter). By increasing the excretion of sodium and water from the bloodstream, it actively decreases extracellular fluid volume and cardiac output, dropping baseline pressure metrics over a steady period.
-
Metoprolol Succinate (25 mg ER): A highly cardio-selective $\beta_1$-adrenergic receptor blocker presented in a specialized extended-release matrix. It reduces sympathetic drive to the heart, actively lowering baseline heart rate, decreasing myocardial contractility, and lowering total cardiac output to smoothly control adrenaline-driven heart flaring spikes over a full 24-hour cycle.
Key Benefits
-
Advanced Triple Action Control: Unites three independent cardiovascular mechanism tracks for intensive blood pressure regulation where dual configurations fail.
-
Optimized Fluid Balancing Profile: The 12.5 mg Chlorthalidone component delivers excellent fluid extraction benefits, actively dropping fluid volume and lowering peripheral resistance.
-
Continuous Heart Rate Regulation: Extended-release 25 mg Metoprolol component smooths out adrenaline-driven heart racing, ensuring steady, predictable cardiac output.
-
Robust 24-Hour Coverage: Designed to release active therapeutic elements steadily over 24 hours, shielding the body from critical early morning stroke or pressure spikes.
-
Trusted Quality: Manufactured under strict pharmaceutical parameters of DH, ensuring precise dosing uniformity and excellent bioavailability.
Directions for Use
-
Take exactly as directed by your cardiologist, nephrologist, or primary physician.
-
Telesky-MCT 25/12.5 should preferably be taken at the exact same time every single morning with or immediately after breakfast.
-
Swallow the tablet whole with a full glass of plain water. Do not crush, break, split, or chew it, as doing so will destroy the specialized extended-release matrix and cause rapid medicine dumping.
-
Important Packing Rule: Telmisartan-containing tablets absorb moisture from the atmosphere very rapidly. Only remove a single tablet from the moisture-proof blister foil configuration at the exact moment of consumption. Do not leave tablets loose inside plastic pillboxes.
Safety & Precautions
-
Do not modify your dose or halt usage suddenly without professional medical clearance, as blood pressure metrics and heart rates can rise rapidly behind tracking boundaries (rebound hypertension).
-
Contraindicated in Pregnancy: Do not use this product if you are pregnant, planning a pregnancy, or nursing. Telmisartan acts directly on the renin-angiotensin system and can cause severe harm or fetal death if used during the second and third trimesters.
-
Monitor your electrolyte panels (especially serum potassium, sodium, and uric acid metrics) and pulse rate regularly, as maximum-strength triple therapies require routine clinical tracking to preserve normal metabolic baselines.
-
Inform your specialist before initialization if you have an underlying history of slow heart rates (bradycardia), heart block conditions, severe kidney or liver vulnerabilities, asthma, or gout patterns.
-
Avoid sudden, rapid positional movements (like jumping up quickly from a bed layout) during the initial few days of therapy to prevent temporary mild dizziness.
-
Keep out of reach of children.
Storage
-
Store in a cool, dry place below 30°C.
-
Protect from direct sunlight, excessive heat sources, and environmental room moisture pools.
-
Always keep the tablets safely sealed inside their original protective blister packaging layout until the exact moment of intake to shield the core components from ambient room humidity.
